To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL

B-cell Acute Lymphoblastic Leukemia Clinical Trial

Official title:

A Early Phase 1 Clinical Trial To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05651191
• Other study ID #: HRAIN01-ALL04-POC
• Status: Recruiting
• Phase: Early Phase 1
• Start date: October 21, 2022
• Est. completion date: September 30, 2025

Study information

• Verified date: December 2022
• Source: Hrain Biotechnology Co., Ltd.
• Contact: Xuedong Sun, M.D.
• Phone: 0086-021-58552006
• Email: sunxuedong[@]dashengbio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a single-arm, open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of human CD19 targeted DASH CAR-T Cells injection, and to preliminarily observe the efficacy of the trial drug in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Description:

Subjects with relapsed/refractory B-cell acute lymphoblastic leukemia can participate if all eligibility criteria are met. Tests required to determine eligibility including disease assessments, a physical exam, Electrocardiograph, Computed tomography（CT）/Magnetic Resonance Imaging(MRI)/Positron Emission Tomography（PET）, and blood draws. Subjects will receive preconditioning chemotherapy prior to the infusion of human CD19 targeted DASH CAR-T Cells injection. After the infusion, subjects will be followed for adverse events, pharmacokinetic/pharmacodynamics characteristics, efficacy of human CD19 targeted DASH CAR-T cells. Study procedures may be performed while hospitalized.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 9
• Est. completion date: September 30, 2025
• Est. primary completion date: September 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:Subjects must meet all of the following criteria to be enrolled:

• 18 to 70 years old (including cut-off value), Male and female;
• Expected survival > 12 weeks;
• ECOG score 0-1;
• Bone marrow examination clearly diagnosed as B-cell acute lymphoblastic leukemia, CD19

positive, and who met one of the following conditions:

1. Those who failed to achieve CR after at least 2 courses of standard chemotherapy or had early relapse after complete remission (<12 months) or late relapse after complete remission (= 12 months) and failed to achieve CR after 1 course of standard chemotherapy;

2. For Ph+ ALL: in addition to receiving at least 2 courses of standard chemotherapy, at least two TKIs should be treated with no complete remission or relapse after complete remission; (Patients who cannot tolerate TKI therapy or have TKI treatment contraindications or have T315i mutation are excluded);

3. Those who relapse after stem cell transplantation are not affected by previous treatments;

• The venous access required for collection can be established and leukapheresis can be carried according to the judgement of investigators;
• Liver, kidney and cardiopulmonary functions meet the following requirements:

1. Serum creatinine = 1.5×ULN;

2. Left ventricular ejection fraction > 50%;

3. Baseline oxygen saturation > 96%;

4. Total bilirubin = 2×ULN; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3×ULN (As judged by the investigator, the elevation of transaminase caused by the ALL disease itself, ALT and AST = 5×ULN);

• Able to understand and sign the Informed Consent Document.

Exclusion Criteria:Any one of the following conditions cannot be selected as a subject:

• Graft-versus-host disease (GVHD), or need to use immunosuppressants after transplantation;
• Patients with hyperleukocytosis (white blood cell count = 50×10^9/L) or whose disease progressed rapidly according to the investigator's judgment at the time of enrollment and cannot ensure the completion of a complete treatment cycle;
• Malignant tumors other than acute lymphoblastic leukemia within 5 years prior to screening, in addition to adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical resection, ductal carcinoma in situ after radical resection and thyroid cancer after radical resection;
• Subjects with positive Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb) and peripheral blood hepatitis B virus (HBV) DNA titer detection higher than the lower limit of the research center can detect; hepatitis C virus (HCV) antibody positive and peripheral blood HCV RNA positive; human immunodeficiency virus (HIV) antibody positive; syphilis detection positive;
• Any instability of systemic disease, including but not limited to unstable angina, cerebrovascular accident, or transient cerebral ischemic (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart failure (New York heart association (NYHA) classification = III), need drug therapy of severe arrhythmia, liver, kidney, or metabolic disease;
• Active or uncontrollable infection requiring systemic therapy within 14 days prior to enrollment;
• Pregnant or lactating woman, and female subject who plans to have a pregnancy within 1 year after cell transfusion, or male subject whose partner plans to have a pregnancy within 1 year after cell transfusion;
• Received CAR-T treatment or other gene therapies before enrollment;
• Patients with symptoms of central nervous system;
• Subjects who are receiving systemic steroid treatment and requiring long-term systemic steroid treatment during the treatment as determined by the investigator before screening (except inhalation or topical use);
• The investigators consider other conditions unsuitable for enrollment.

Related Conditions & MeSH terms

• B-cell Acute Lymphoblastic Leukemia
• Leukemia
• Leukemia, Lymphoid
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Drug:
• Human CD19 Targeted DASH CAR-T Cells Injection
Autologous genetically modified anti-CD19 CAR transduced T cells

Locations

Country	Name	City	State
China	The Second Affiliated Hospital of Nanchang University	Nanchang	Jiangxi

Sponsors (2)

Lead Sponsor	Collaborator
Hrain Biotechnology Co., Ltd.	Second Affiliated Hospital of Nanchang University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose limited toxicity (DLT)	Safety Indicators	28 days post infusion
Secondary	Pharmacokinetics parameters - the highest concentration of Human CD19 Targeted DASH CAR-T Cells amplified in peripheral blood after reinfusion	Effectiveness Metrics	2 years post infusion
Secondary	Pharmacokinetics parameters - the time to reach the highest concentration of Human CD19 Targeted DASH CAR-T Cells amplified in peripheral blood after reinfusion	Effectiveness Metrics	2 years post infusion
Secondary	Pharmacokinetics parameters - the 28-day area under the curve of Human CD19 Targeted DASH CAR-T Cells amplified in peripheral blood after reinfusion	Effectiveness Metrics	2 years post infusion
Secondary	Pharmacodynamics characteristics - the detection values of IL-6, IFN-?, IL-15 cytokines in peripheral blood	Effectiveness Metrics	2 years post infusion
Secondary	Overall response rate (ORR, include CR and CRi) after administration	Effectiveness Metrics	3 months post infusion
Secondary	Duration of remission (DOR) after administration	Effectiveness Metrics	2 years post infusion
Secondary	Overall Survival (OS) after administration	Effectiveness Metrics	2 years post infusion